Curespec News
4 articles
Startup aiming to keep kidney patients off dialysis - ISRAEL21c
Israeli medical device company Curespec has developed a device, Nephrospec, which it claims can postpone dialysis treatment for stage three and four chronic kidney disease (CKD) patients by up to 12 months. The company is now conducting clinical trials to prove the devices efficacy. Nephrospec is also being promoted as an effective treatment for hypertension. The company has raised over $1 million from private investors, received a $3.4 million grant from the National Institutes of Health, and an initial $3 million investment from Medispec. It is now aiming to raise $10 million in a seed funding round to complete its clinical trials.
InvestmentExpand
Meet the man who is making medical devices for the masses
Avner Spector, founder of Medispec and Curespec, has been improving lives with his medical equipment designs. Medispec, founded in 1992, operates in 44 countries and was the first to apply electro-Hydraulic Acoustic Therapy (eHAT) to sexual health indications. Curespecs first product, Nephrospec, uses eHAT to treat chronic kidney disease (CKD) by promoting new blood vessel formation and restoring damaged tissue function. The treatment is painless, and improvement is seen after only six sessions over a three-week period. Spector believes the technology will soon be proven effective for other kidney diseases and even kidney transplants.
CustomersExpand
הסטארט-אפ הישראלי שמתקן את הכליות שלכם וחוסך מיליארדים למערכת הבריאות | כלכליסט
Curespec, an Israeli startup, is pioneering a unique low-intensity shockwave technology to delay dialysis needs and improve kidney function, potentially reducing healthcare costs significantly. The company is currently seeking investors to expand its operations globally. Clinical studies in Japan, the US, and Israel have shown promising results, including reduced treatment times and improved kidney function, with no significant adverse events reported. The NIH has recognized the technologys importance, funding initial research with $3.4 million. Curespecs device has received CE approval for Europe and is expected to be marketed soon. In January 2023, Curespec won a Chinese innovation competition, attracting interest from Fosun. The company is poised for substantial growth, with opportunities for investors to join.
Investment
N12 - גלי קול שדוחים את הטיפול בדיאליזה: התקווה החדשה של חולי...
Israeli start-up Curespec has developed a device called NephroSpec that uses sound waves to stimulate the growth of new blood vessels in the kidneys, potentially delaying the need for dialysis in patients with chronic kidney disease. The device has undergone successful trials in Israel, Japan, and the Philippines, and has received approval from the European Union and Israels Ministry of Health. Curespec, which was founded in December 2020, has raised $3.4 million from the National Institutes of Health and $500,000 from private investors. The company is now seeking to raise an additional $2 million at a valuation of $14 million.
Investment
